Volume 14, Number 2—February 2008
Letter
Increasing Resistance in Commensal Escherichia coli, Bolivia and Peru
, Lucia Pallecchi†, Costanza Fiorelli*, Tiziana Di Maggio†, Connie Fernandez‡, Ana Liz Villagran§, Antonia Mantella*, Filippo Bartalesi*, Marianne Strohmeyer*, Angela Bechini*, Herlan Gamboa§, Hugo Rodriguez‡, Charlotte Kristiansson¶, Göran Kronvall¶, Eduardo Gotuzzo#, Franco Paradisi*, and Gian Maria Rossolini†
Table
Antimicrobial drug–resistance rates of Escherichia coli as part of commensal flora in children, Bolivia and Peru, 2002 and 2005* *Expanded Table available online at www.cdc.gov/EID/content/14/2/338-T.htm.
| Drug† | 2002 | 2005 | p value‡ |
|---|---|---|---|
| AMP | 95 | 96 | <0.05 |
| CRO | 0.1 | 1.7 | <0.001 |
| TET | 93 | 93 | NS |
| SXT | 94 | 94 | NS |
| CHL | 70 | 69 | NS |
| STR | 82 | 92 | <0.001 |
| KAN | 28 | 29 | <0.05 |
| GEN | 21 | 27 | <0.001 |
| AMK | 0.4 | 0.1 | NA |
| NAL | 35 | 57 | <0.001 |
| CIP | 18 | 33 | <0.001 |
Prevalence expressed as percentages. In 2002, n = 3,174, mean age 34.8 mo; in 2005, n = 3,193, mean age 33.7 mo (mean age p<0.05).
†AMP, ampicillin; CRO, ceftriaxone; TET, tetracycline; SXT, trimethoprim-sulfamethoxazole; CHL, chloramphenicol; STR, streptomycin; KAN, kanamycin; GEN, gentamicin; AMK, amikacin; NAL, nalidixic acid; CIP, ciprofloxacin.
‡Wald test applied to establish the statistical significance of parameters obtained from logistic regression analysis; NS, not significant; NA, not applicable (due to lack of variability of data).